Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives
摘要:
Two series of novel diaryl ureas have been designed and synthesized, with their in vitro antitumor effect screened on human non-small cell lung cancer (NSCLC) cell line A549 and human breast cancer cell line MDA-MB-231. Some target compounds demonstrated significant inhibitory activities against both cell lines. Compared to contrast drug Sorafenib, 1b, 1d, 1f, 1i were found to demonstrate more potent antitumor activities. The structures of all the newly synthesized compounds were determined by (1)H, (13)C NMR, MS, IR and elementary analysis.
Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives
摘要:
Two series of novel diaryl ureas have been designed and synthesized, with their in vitro antitumor effect screened on human non-small cell lung cancer (NSCLC) cell line A549 and human breast cancer cell line MDA-MB-231. Some target compounds demonstrated significant inhibitory activities against both cell lines. Compared to contrast drug Sorafenib, 1b, 1d, 1f, 1i were found to demonstrate more potent antitumor activities. The structures of all the newly synthesized compounds were determined by (1)H, (13)C NMR, MS, IR and elementary analysis.
[EN] INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS<br/>[FR] INHIBITEURS DE LA VOIE DE SIGNALISATION NOTCH ET LEUR UTILISATION DANS LE TRAITEMENT DE CANCERS
申请人:CELLESTIA BIOTECH AG
公开号:WO2020208139A1
公开(公告)日:2020-10-15
The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.